wide
rang
rna
fever
may
absent
transplant
recipi
pneumonia
may
sole
present
sign
symptom
fever
respiratori
symptom
prompt
consider
respiratori
viral
infect
potenti
caus
viral
shed
usual
prolong
among
transplant
recipi
prolong
shed
seen
even
use
antivir
therefor
may
contribut
increas
risk
resist
variant
emerg
sever
studi
dfa
test
primari
patient
specimen
document
sensit
approach
pcr
certain
virus
dfa
test
limit
lack
reagent
virus
hmpv
rhinoviru
coronaviru
appear
less
sensit
pcr
detect
dual
infect
like
pcr
though
dfa
test
detect
sever
virus
singl
specimen
wide
rang
pcrbase
assay
detect
respiratori
viru
commerci
avail
mani
center
local
develop
assay
detect
select
virus
avail
assay
abl
screen
wide
rang
pathogen
tandem
mani
test
transplant
popul
nucleic
acid
amplif
assay
appear
sensit
diagnost
tool
avail
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
therefor
prefer
test
method
immunocompromis
patient
transmiss
occur
inhal
infecti
droplet
contact
fomit
form
influenza
particularli
avian
influenza
may
spread
aerosol
patient
known
suspect
influenza
isol
patient
use
standard
droplet
precaut
two
type
influenza
vaccin
current
avail
number
formul
inject
kill
vaccin
singl
inhal
live
attenu
vaccin
inject
vaccin
studi
transplant
patient
found
safe
associ
increas
risk
reject
advers
outcom
potenti
replic
live
attenu
vaccin
use
contraind
highli
immun
suppress
patient
close
contact
antivir
chemoprophylaxi
consid
altern
supplement
vaccin
agent
activ
circul
influenza
strain
use
random
doubleblind
studi
oseltamivir
prophylaxi
highrisk
transplant
recipi
found
protect
efficaci
note
also
receiv
vaccin
two
class
antivir
compound
approv
treatment
influenza
inhibitor
amantadin
rimantadin
final
resist
avail
antivir
complic
routin
manag
influenza
gener
nearli
influenza
virus
resist
inhibitor
resist
affect
amantadin
rimantadin
equal
mani
influenza
virus
develop
resist
oseltamivir
although
current
retain
suscept
zanamivir
also
suscept
inhibitor
earli
acquisit
rsv
transplant
augment
immunosuppress
associ
increas
sever
diseas
studi
transmiss
occur
inhal
infecti
droplet
contact
fomit
patient
known
suspect
rsv
isol
patient
use
standard
contact
precaut
prophylaxi
rsvspecif
monoclon
antibodi
palivizumab
high
titer
rsvivig
shown
effect
specif
group
highrisk
infant
young
children
howev
studi
conduct
evalu
use
transplant
set
cost
weight
adjust
dose
product
adult
would
extrem
high
despit
expert
would
support
use
immunoprophylaxi
children
less
year
age
receiv
transplant
rsv
season
iii
survey
data
suggest
antibodybas
prophylaxi
commonli
use
among
pediatr
transplant
center
approv
vaccin
treatment
rsv
given
limit
data
treatment
rsv
support
care
recommend
reduct
immun
suppress
consid
particularli
sever
diseas
role
specif
antivir
treatment
controversi
ribavirin
shown
vitro
activ
rsv
aerosol
form
drug
approv
treatment
lower
respiratori
tract
diseas
due
rsv
certain
atrisk
popul
despit
fda
approv
convinc
data
describ
clinic
efficaci
agent
lack
consensu
util
drug
treatment
rsv
diseas
current
exist
publish
data
treatment
rsv
diseas
solid
organ
transplant
recipi
limit
experi
stem
cell
transplant
popul
suggest
use
aerosol
ribavirin
may
reduc
mortal
associ
sever
rsv
infect
particularli
affect
lower
airway
combin
aerosol
ribavirin
antibodybas
intervent
includ
igiv
rsvig
palivizumab
appear
even
greater
impact
mortal
mani
expert
therefor
would
recommend
use
combin
aerosol
ribavirin
antibodi
prepar
treatment
sever
rsv
infect
base
upon
publish
experi
pediatr
organ
transplant
recipi
patient
without
risk
factor
sever
diseas
upper
respiratori
infect
unlik
benefit
aerosol
ribavirin
publish
report
success
treatment
rsv
lung
transplant
recipi
oral
iv
ribavirin
without
corticosteroid
studi
need
determin
clinic
efficaci
altern
risk
advers
effect
notabl
hemolyt
anemia
parainfluenza
pneumoviru
four
type
commonli
caus
diseas
human
type
piv
type
tend
circul
sporad
fall
winter
month
temper
area
wherea
type
occur
year
round
type
least
commonli
isol
epidemiolog
still
defin
transmiss
occur
via
persontoperson
spread
direct
contact
infecti
secret
fomit
diseas
seriou
particularli
pediatr
transplant
recipi
lung
transplant
recipi
age
although
respiratori
virus
associ
increas
risk
progress
oblit
bronchiol
lung
transplant
recipi
associ
appear
clearest
strongest
piv
lower
tract
diseas
patient
known
suspect
piv
isol
patient
use
standard
contact
precaut
approv
vaccin
recogn
prevent
antivir
agent
although
use
igiv
ribavirin
associ
benefit
manag
piv
infect
stem
cell
transplant
recipi
ribavirin
vitro
activ
use
treat
lung
transplant
recipi
lower
tract
diseas
expert
also
consid
use
igiv
well
hmpv
discov
rel
newli
recogn
pneumoviru
clinic
pattern
similar
rsv
signific
caus
diseas
transplant
recipi
pneumovirus
vaccin
prevent
focus
tight
infect
control
measur
includ
contact
precaut
case
report
anim
data
suggest
ribavirin
igiv
consid
manag
sever
case
hmpv
support
care
remain
mainstay
treatment
human
rhinovirus
hrv
member
picornavirida
famili
common
caus
cold
adult
children
recogn
caus
clinic
signific
diseas
transplant
recipi
fatal
case
describ
fatal
associ
coinfect
prolong
shed
minim
symptom
describ
particularli
lung
transplant
recipi
clinic
import
prolong
shed
fulli
defin
although
could
potenti
pose
threat
nosocomi
transmiss
pleconaril
studi
extens
healthi
adult
rhinovir
upper
respiratori
infect
well
toler
led
faster
resolut
symptom
rapid
improv
symptom
score
clearanc
viru
nasal
mucou
howev
approv
use
fda
due
safeti
concern
current
approv
prevent
therapeut
intervent
use
molecular
diagnost
wider
rang
respiratori
virus
isol
mani
virus
newli
recogn
variant
coronaviru
polyomavirus
wu
ki
virus
bocaviru
wide
studi
transplant
recipi
clinic
impact
fulli
assess
sever
sometim
fatal
case
virus
immunocompromis
patient
recogn
consid
differenti
diagnosi
patient
present
sever
lower
tract
diseas
newer
agent
challeng
diagnos
includ
routin
clinic
avail
diagnost
test
addit
optim
manag
agent
defin
although
respiratori
virus
increasingli
recogn
caus
morbid
mortal
transplant
recipi
still
much
learn
impact
rna
respiratori
viral
infect
virus
prospect
studi
involv
inpati
outpati
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
particular
studi
longterm
consequ
infect
even
mild
asymptomat
infect
need
particularli
lung
transplant
recipi
lower
tract
infect
associ
increas
risk
chronic
reject
prospect
studi
use
contemporari
molecular
diagnost
tool
also
need
defin
efficaci
cost
prevent
intervent
particularli
highrisk
pediatr
popul
final
prospect
therapeut
trial
need
defin
optim
time
durat
treatment
regimen
virus
need
